Active Pharmaceutical Ingredients(API) Market Report

Europe Active Pharmaceutical Ingredients(API) Market Size, Status and Forecast 2014-2026

  • POSTDATE：Mar 19, 2020
  • PAGES：186
  • REPORT CODE：GMM512884
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Active Pharmaceutical Ingredients(API) market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 3.2% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Active Pharmaceutical Ingredients(API) Market Segmentations:

    By Player:

    • Novartis International

    • AbbVie

    • Lonza Group

    • Eli Lilly and Company

    • Biocon

    • Hisun Pharmacy

    • Merck & Co

    • Pfizer

    • North China Pharmaceutical Group

    • Haerbin Pharmaceutical Group

    • Bristol-Myers Squibb

    • Huahai Pharmaceutical

    • Sun Pharmaceutical Industries

    • DSM

    • GlaxoSmithKline

    • Johnson & Johnson

    • Bayer

    • Aurobindo Pharma

    • Shandong Xinhua Pharmaceutical

    • Jiangsu Hengrui Medicine

    • Lupin

    • Sanofi

    • Teva Pharmaceutical

    • Boehringer Ingelheim

    • Shandong Lukang Pharmaceutical

    By Type:

    • Synthetic APIs

    • Biotech APIs

    By End-User:

    • Oncology

    • Diabetes

    • Cardiovascular Disease

    • CNS and Neurological Disorders

    • Endocrinology

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Active Pharmaceutical Ingredients(API) Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of Synthetic APIs from 2014 to 2026

    • 1.3.2 Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of Biotech APIs from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of Oncology from 2014 to 2026

    • 1.4.2 Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of Diabetes from 2014 to 2026

    • 1.4.3 Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of Cardiovascular Disease from 2014 to 2026

    • 1.4.4 Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of CNS and Neurological Disorders from 2014 to 2026

    • 1.4.5 Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of Endocrinology from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Active Pharmaceutical Ingredients(API) Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Active Pharmaceutical Ingredients(API) by Major Types

      • 3.4.1 Market Size and Growth Rate of Synthetic APIs

      • 3.4.2 Market Size and Growth Rate of Biotech APIs

    4 Segmentation of Active Pharmaceutical Ingredients(API) Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Active Pharmaceutical Ingredients(API) by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Active Pharmaceutical Ingredients(API) for Oncology

      • 4.4.2 Market Size and Growth Rate of Active Pharmaceutical Ingredients(API) for Diabetes

      • 4.4.3 Market Size and Growth Rate of Active Pharmaceutical Ingredients(API) for Cardiovascular Disease

      • 4.4.4 Market Size and Growth Rate of Active Pharmaceutical Ingredients(API) for CNS and Neurological Disorders

      • 4.4.5 Market Size and Growth Rate of Active Pharmaceutical Ingredients(API) for Endocrinology

    5 Market Analysis by Major Regions

    • 5.1 Europe Active Pharmaceutical Ingredients(API) Production Analysis by Top Regions

    • 5.2 Europe Active Pharmaceutical Ingredients(API) Consumption Analysis by Top Regions

    • 5.3 Europe Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

      • 5.3.3 France Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

    6 Product Circulation of Active Pharmaceutical Ingredients(API) Market among Top Countries

    • 6.1 Top 5 Export Countries in Active Pharmaceutical Ingredients(API) Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Active Pharmaceutical Ingredients(API) Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Active Pharmaceutical Ingredients(API) Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Active Pharmaceutical Ingredients(API) Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Active Pharmaceutical Ingredients(API) Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Active Pharmaceutical Ingredients(API) Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Active Pharmaceutical Ingredients(API) Landscape Analysis

    • 7.1 Germany Active Pharmaceutical Ingredients(API) Landscape Analysis by Major Types

    • 7.2 Germany Active Pharmaceutical Ingredients(API) Landscape Analysis by Major End-Users

    8. UK Active Pharmaceutical Ingredients(API) Landscape Analysis

    • 8.1 UK Active Pharmaceutical Ingredients(API) Landscape Analysis by Major Types

    • 8.2 UK Active Pharmaceutical Ingredients(API) Landscape Analysis by Major End-Users

    9. France Active Pharmaceutical Ingredients(API) Landscape Analysis

    • 9.1 France Active Pharmaceutical Ingredients(API) Landscape Analysis by Major Types

    • 9.2 France Active Pharmaceutical Ingredients(API) Landscape Analysis by Major End-Users

    10. Italy Active Pharmaceutical Ingredients(API) Landscape Analysis

    • 10.1 Italy Active Pharmaceutical Ingredients(API) Landscape Analysis by Major Types

    • 10.2 Italy Active Pharmaceutical Ingredients(API) Landscape Analysis by Major End-Users

    11. Spain Active Pharmaceutical Ingredients(API) Landscape Analysis

    • 11.1 Spain Active Pharmaceutical Ingredients(API) Landscape Analysis by Major Types

    • 11.2 Spain Active Pharmaceutical Ingredients(API) Landscape Analysis by Major End-Users

    12. Poland Active Pharmaceutical Ingredients(API) Landscape Analysis

    • 12.1 Poland Active Pharmaceutical Ingredients(API) Landscape Analysis by Major Types

    • 12.2 Poland Active Pharmaceutical Ingredients(API) Landscape Analysis by Major End-Users

    13. Russia Active Pharmaceutical Ingredients(API) Landscape Analysis

    • 13.1 Russia Active Pharmaceutical Ingredients(API) Landscape Analysis by Major Types

    • 13.2 Russia Active Pharmaceutical Ingredients(API) Landscape Analysis by Major End-Users

    14. Switzerland Active Pharmaceutical Ingredients(API) Landscape Analysis

    • 14.1 Switzerland Active Pharmaceutical Ingredients(API) Landscape Analysis by Major Types

    • 14.2 Switzerland Active Pharmaceutical Ingredients(API) Landscape Analysis by Major End-Users

    15. Turkey Active Pharmaceutical Ingredients(API) Landscape Analysis

    • 15.1 Turkey Active Pharmaceutical Ingredients(API) Landscape Analysis by Major Types

    • 15.2 Turkey Active Pharmaceutical Ingredients(API) Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Landscape Analysis by Top Countries

      • 16.3.1 Denmark Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate

      • 16.3.2 Finland Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate

      • 16.3.3 Norway Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate

      • 16.3.4 Sweden Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate

      • 16.3.6 Iceland Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Landscape Analysis by Top Countries

      • 17.3.1 Belgium Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate

      • 17.3.2 Netherlands Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate

      • 17.3.3 Luxembourg Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Landscape Analysis by Top Countries

      • 18.3.1 Estonia Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate

      • 18.3.2 Latvia Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate

      • 18.3.3 Lithuania Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Novartis International

      • 19.1.1 Novartis International Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 AbbVie

      • 19.2.1 AbbVie Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Lonza Group

      • 19.3.1 Lonza Group Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Eli Lilly and Company

      • 19.4.1 Eli Lilly and Company Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Biocon

      • 19.5.1 Biocon Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Hisun Pharmacy

      • 19.6.1 Hisun Pharmacy Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 Merck & Co

      • 19.7.1 Merck & Co Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 Pfizer

      • 19.8.1 Pfizer Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 North China Pharmaceutical Group

      • 19.9.1 North China Pharmaceutical Group Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Haerbin Pharmaceutical Group

      • 19.10.1 Haerbin Pharmaceutical Group Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Bristol-Myers Squibb

      • 19.11.1 Bristol-Myers Squibb Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Huahai Pharmaceutical

      • 19.12.1 Huahai Pharmaceutical Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Sun Pharmaceutical Industries

      • 19.13.1 Sun Pharmaceutical Industries Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 DSM

      • 19.14.1 DSM Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 GlaxoSmithKline

      • 19.15.1 GlaxoSmithKline Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 Johnson & Johnson

      • 19.16.1 Johnson & Johnson Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Bayer

      • 19.17.1 Bayer Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Aurobindo Pharma

      • 19.18.1 Aurobindo Pharma Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    • 19.19 Shandong Xinhua Pharmaceutical

      • 19.19.1 Shandong Xinhua Pharmaceutical Company Profile and Development Status

      • 19.19.2 Market Performance

      • 19.19.3 Product and Service Introduction

    • 19.20 Jiangsu Hengrui Medicine

      • 19.20.1 Jiangsu Hengrui Medicine Company Profile and Development Status

      • 19.20.2 Market Performance

      • 19.20.3 Product and Service Introduction

    • 19.21 Lupin

      • 19.21.1 Lupin Company Profile and Development Status

      • 19.21.2 Market Performance

      • 19.21.3 Product and Service Introduction

    • 19.22 Sanofi

      • 19.22.1 Sanofi Company Profile and Development Status

      • 19.22.2 Market Performance

      • 19.22.3 Product and Service Introduction

    • 19.23 Teva Pharmaceutical

      • 19.23.1 Teva Pharmaceutical Company Profile and Development Status

      • 19.23.2 Market Performance

      • 19.23.3 Product and Service Introduction

    • 19.24 Boehringer Ingelheim

      • 19.24.1 Boehringer Ingelheim Company Profile and Development Status

      • 19.24.2 Market Performance

      • 19.24.3 Product and Service Introduction

    • 19.25 Shandong Lukang Pharmaceutical

      • 19.25.1 Shandong Lukang Pharmaceutical Company Profile and Development Status

      • 19.25.2 Market Performance

      • 19.25.3 Product and Service Introduction

    The List of Tables and Figures (Totals 103 Figures and 152 Tables)

    • Figure Product Picture

    • Figure Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of Synthetic APIs from 2014 to 2026

    • Figure Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of Biotech APIs from 2014 to 2026

    • Figure Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of Oncology from 2014 to 2026

    • Figure Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of Diabetes from 2014 to 2026

    • Figure Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of Cardiovascular Disease from 2014 to 2026

    • Figure Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of CNS and Neurological Disorders from 2014 to 2026

    • Figure Europe Active Pharmaceutical Ingredients(API) Market Size and Growth Rate of Endocrinology from 2014 to 2026

    • Figure Germany Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure UK Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure France Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Active Pharmaceutical Ingredients(API) Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Active Pharmaceutical Ingredients(API) Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Active Pharmaceutical Ingredients(API)

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Active Pharmaceutical Ingredients(API) by Different Types from 2014 to 2026

    • Table Consumption Share of Active Pharmaceutical Ingredients(API) by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Synthetic APIs

    • Figure Market Size and Growth Rate of Biotech APIs

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Active Pharmaceutical Ingredients(API) by Different End-Users from 2014 to 2026

    • Table Consumption Share of Active Pharmaceutical Ingredients(API) by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Oncology

    • Figure Market Size and Growth Rate of Diabetes

    • Figure Market Size and Growth Rate of Cardiovascular Disease

    • Figure Market Size and Growth Rate of CNS and Neurological Disorders

    • Figure Market Size and Growth Rate of Endocrinology

    • Table Europe Active Pharmaceutical Ingredients(API) Production by Major Regions

    • Table Europe Active Pharmaceutical Ingredients(API) Production Share by Major Regions

    • Figure Europe Active Pharmaceutical Ingredients(API) Production Share by Major Countries and Regions in 2014

    • Table Europe Active Pharmaceutical Ingredients(API) Consumption by Major Regions

    • Table Europe Active Pharmaceutical Ingredients(API) Consumption Share by Major Regions

    • Table Germany Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

    • Table UK Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

    • Table France Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

    • Table Italy Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

    • Table Spain Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

    • Table Poland Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

    • Table Russia Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

    • Table Switzerland Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

    • Table Turkey Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Active Pharmaceutical Ingredients(API) Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Active Pharmaceutical Ingredients(API) Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Active Pharmaceutical Ingredients(API) Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Active Pharmaceutical Ingredients(API) Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Active Pharmaceutical Ingredients(API) Consumption by Types from 2014 to 2026

    • Table Germany Active Pharmaceutical Ingredients(API) Consumption Share by Types from 2014 to 2026

    • Table Germany Active Pharmaceutical Ingredients(API) Consumption by End-Users from 2014 to 2026

    • Table Germany Active Pharmaceutical Ingredients(API) Consumption Share by End-Users from 2014 to 2026

    • Table UK Active Pharmaceutical Ingredients(API) Consumption by Types from 2014 to 2026

    • Table UK Active Pharmaceutical Ingredients(API) Consumption Share by Types from 2014 to 2026

    • Table UK Active Pharmaceutical Ingredients(API) Consumption by End-Users from 2014 to 2026

    • Table UK Active Pharmaceutical Ingredients(API) Consumption Share by End-Users from 2014 to 2026

    • Table France Active Pharmaceutical Ingredients(API) Consumption by Types from 2014 to 2026

    • Table France Active Pharmaceutical Ingredients(API) Consumption Share by Types from 2014 to 2026

    • Table France Active Pharmaceutical Ingredients(API) Consumption by End-Users from 2014 to 2026

    • Table France Active Pharmaceutical Ingredients(API) Consumption Share by End-Users from 2014 to 2026

    • Table Italy Active Pharmaceutical Ingredients(API) Consumption by Types from 2014 to 2026

    • Table Italy Active Pharmaceutical Ingredients(API) Consumption Share by Types from 2014 to 2026

    • Table Italy Active Pharmaceutical Ingredients(API) Consumption by End-Users from 2014 to 2026

    • Table Italy Active Pharmaceutical Ingredients(API) Consumption Share by End-Users from 2014 to 2026

    • Table Spain Active Pharmaceutical Ingredients(API) Consumption by Types from 2014 to 2026

    • Table Spain Active Pharmaceutical Ingredients(API) Consumption Share by Types from 2014 to 2026

    • Table Spain Active Pharmaceutical Ingredients(API) Consumption by End-Users from 2014 to 2026

    • Table Spain Active Pharmaceutical Ingredients(API) Consumption Share by End-Users from 2014 to 2026

    • Table Poland Active Pharmaceutical Ingredients(API) Consumption by Types from 2014 to 2026

    • Table Poland Active Pharmaceutical Ingredients(API) Consumption Share by Types from 2014 to 2026

    • Table Poland Active Pharmaceutical Ingredients(API) Consumption by End-Users from 2014 to 2026

    • Table Poland Active Pharmaceutical Ingredients(API) Consumption Share by End-Users from 2014 to 2026

    • Table Russia Active Pharmaceutical Ingredients(API) Consumption by Types from 2014 to 2026

    • Table Russia Active Pharmaceutical Ingredients(API) Consumption Share by Types from 2014 to 2026

    • Table Russia Active Pharmaceutical Ingredients(API) Consumption by End-Users from 2014 to 2026

    • Table Russia Active Pharmaceutical Ingredients(API) Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Active Pharmaceutical Ingredients(API) Consumption by Types from 2014 to 2026

    • Table Switzerland Active Pharmaceutical Ingredients(API) Consumption Share by Types from 2014 to 2026

    • Table Switzerland Active Pharmaceutical Ingredients(API) Consumption by End-Users from 2014 to 2026

    • Table Switzerland Active Pharmaceutical Ingredients(API) Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Active Pharmaceutical Ingredients(API) Consumption by Types from 2014 to 2026

    • Table Turkey Active Pharmaceutical Ingredients(API) Consumption Share by Types from 2014 to 2026

    • Table Turkey Active Pharmaceutical Ingredients(API) Consumption by End-Users from 2014 to 2026

    • Table Turkey Active Pharmaceutical Ingredients(API) Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Active Pharmaceutical Ingredients(API) Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Active Pharmaceutical Ingredients(API) Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Active Pharmaceutical Ingredients(API) Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Active Pharmaceutical Ingredients(API) Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Novartis International

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis International

    • Figure Sales and Growth Rate Analysis of Novartis International

    • Figure Revenue and Market Share Analysis of Novartis International

    • Table Product and Service Introduction of Novartis International

    • Table Company Profile and Development Status of AbbVie

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AbbVie

    • Figure Sales and Growth Rate Analysis of AbbVie

    • Figure Revenue and Market Share Analysis of AbbVie

    • Table Product and Service Introduction of AbbVie

    • Table Company Profile and Development Status of Lonza Group

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Lonza Group

    • Figure Sales and Growth Rate Analysis of Lonza Group

    • Figure Revenue and Market Share Analysis of Lonza Group

    • Table Product and Service Introduction of Lonza Group

    • Table Company Profile and Development Status of Eli Lilly and Company

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly and Company

    • Figure Sales and Growth Rate Analysis of Eli Lilly and Company

    • Figure Revenue and Market Share Analysis of Eli Lilly and Company

    • Table Product and Service Introduction of Eli Lilly and Company

    • Table Company Profile and Development Status of Biocon

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Biocon

    • Figure Sales and Growth Rate Analysis of Biocon

    • Figure Revenue and Market Share Analysis of Biocon

    • Table Product and Service Introduction of Biocon

    • Table Company Profile and Development Status of Hisun Pharmacy

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Hisun Pharmacy

    • Figure Sales and Growth Rate Analysis of Hisun Pharmacy

    • Figure Revenue and Market Share Analysis of Hisun Pharmacy

    • Table Product and Service Introduction of Hisun Pharmacy

    • Table Company Profile and Development Status of Merck & Co

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck & Co

    • Figure Sales and Growth Rate Analysis of Merck & Co

    • Figure Revenue and Market Share Analysis of Merck & Co

    • Table Product and Service Introduction of Merck & Co

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of North China Pharmaceutical Group

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of North China Pharmaceutical Group

    • Figure Sales and Growth Rate Analysis of North China Pharmaceutical Group

    • Figure Revenue and Market Share Analysis of North China Pharmaceutical Group

    • Table Product and Service Introduction of North China Pharmaceutical Group

    • Table Company Profile and Development Status of Haerbin Pharmaceutical Group

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Haerbin Pharmaceutical Group

    • Figure Sales and Growth Rate Analysis of Haerbin Pharmaceutical Group

    • Figure Revenue and Market Share Analysis of Haerbin Pharmaceutical Group

    • Table Product and Service Introduction of Haerbin Pharmaceutical Group

    • Table Company Profile and Development Status of Bristol-Myers Squibb

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bristol-Myers Squibb

    • Figure Sales and Growth Rate Analysis of Bristol-Myers Squibb

    • Figure Revenue and Market Share Analysis of Bristol-Myers Squibb

    • Table Product and Service Introduction of Bristol-Myers Squibb

    • Table Company Profile and Development Status of Huahai Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Huahai Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Huahai Pharmaceutical

    • Figure Revenue and Market Share Analysis of Huahai Pharmaceutical

    • Table Product and Service Introduction of Huahai Pharmaceutical

    • Table Company Profile and Development Status of Sun Pharmaceutical Industries

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sun Pharmaceutical Industries

    • Figure Sales and Growth Rate Analysis of Sun Pharmaceutical Industries

    • Figure Revenue and Market Share Analysis of Sun Pharmaceutical Industries

    • Table Product and Service Introduction of Sun Pharmaceutical Industries

    • Table Company Profile and Development Status of DSM

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of DSM

    • Figure Sales and Growth Rate Analysis of DSM

    • Figure Revenue and Market Share Analysis of DSM

    • Table Product and Service Introduction of DSM

    • Table Company Profile and Development Status of GlaxoSmithKline

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of GlaxoSmithKline

    • Figure Sales and Growth Rate Analysis of GlaxoSmithKline

    • Figure Revenue and Market Share Analysis of GlaxoSmithKline

    • Table Product and Service Introduction of GlaxoSmithKline

    • Table Company Profile and Development Status of Johnson & Johnson

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Johnson & Johnson

    • Figure Sales and Growth Rate Analysis of Johnson & Johnson

    • Figure Revenue and Market Share Analysis of Johnson & Johnson

    • Table Product and Service Introduction of Johnson & Johnson

    • Table Company Profile and Development Status of Bayer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Bayer

    • Figure Sales and Growth Rate Analysis of Bayer

    • Figure Revenue and Market Share Analysis of Bayer

    • Table Product and Service Introduction of Bayer

    • Table Company Profile and Development Status of Aurobindo Pharma

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Aurobindo Pharma

    • Figure Sales and Growth Rate Analysis of Aurobindo Pharma

    • Figure Revenue and Market Share Analysis of Aurobindo Pharma

    • Table Product and Service Introduction of Aurobindo Pharma

    • Table Company Profile and Development Status of Shandong Xinhua Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Shandong Xinhua Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Shandong Xinhua Pharmaceutical

    • Figure Revenue and Market Share Analysis of Shandong Xinhua Pharmaceutical

    • Table Product and Service Introduction of Shandong Xinhua Pharmaceutical

    • Table Company Profile and Development Status of Jiangsu Hengrui Medicine

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Jiangsu Hengrui Medicine

    • Figure Sales and Growth Rate Analysis of Jiangsu Hengrui Medicine

    • Figure Revenue and Market Share Analysis of Jiangsu Hengrui Medicine

    • Table Product and Service Introduction of Jiangsu Hengrui Medicine

    • Table Company Profile and Development Status of Lupin

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Lupin

    • Figure Sales and Growth Rate Analysis of Lupin

    • Figure Revenue and Market Share Analysis of Lupin

    • Table Product and Service Introduction of Lupin

    • Table Company Profile and Development Status of Sanofi

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi

    • Figure Sales and Growth Rate Analysis of Sanofi

    • Figure Revenue and Market Share Analysis of Sanofi

    • Table Product and Service Introduction of Sanofi

    • Table Company Profile and Development Status of Teva Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Teva Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Teva Pharmaceutical

    • Figure Revenue and Market Share Analysis of Teva Pharmaceutical

    • Table Product and Service Introduction of Teva Pharmaceutical

    • Table Company Profile and Development Status of Boehringer Ingelheim

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Boehringer Ingelheim

    • Figure Sales and Growth Rate Analysis of Boehringer Ingelheim

    • Figure Revenue and Market Share Analysis of Boehringer Ingelheim

    • Table Product and Service Introduction of Boehringer Ingelheim

    • Table Company Profile and Development Status of Shandong Lukang Pharmaceutical

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Shandong Lukang Pharmaceutical

    • Figure Sales and Growth Rate Analysis of Shandong Lukang Pharmaceutical

    • Figure Revenue and Market Share Analysis of Shandong Lukang Pharmaceutical

    • Table Product and Service Introduction of Shandong Lukang Pharmaceutical

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US